# psoriasis - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 15751
- Completion tokens: 2488
- Reasoning tokens: 582
- Total tokens: 18239
- API requests reported: 1
- Elapsed seconds: 54.024
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: xAI

---
**Overall biological interpretation**  
The transcriptomic profile from psoriatic lesional skin versus normal control skin is dominated by strong upregulation (90 of 100 selected genes) of epidermal-keratinocyte and inflammatory response genes, with only modest downregulation. Representative genes such as *IL36A* (log2FC 11.37), *DEFB4A* (11.18), *S100A8* (7.73), *SPRR2A* (7.31), *SERPINB4* (9.12), and *IL19* (7.58) collectively indicate massive keratinocyte hyperproliferation, impaired epidermal barrier formation, and activation of innate/adaptive immune signaling. This pattern aligns with the chronic epidermal hyperplasia and neutrophil-rich inflammation that define psoriasis plaques, where cornified-envelope genes (*SPRR1B*, *SPRR2* family) and S100/calgranulin proteins amplify local inflammation while defensins and IL-36 family members drive antimicrobial and IL-17/IL-36-mediated responses.

**Core biological programs**  
1. **Epidermal hyperplasia and cornified-envelope formation**  
   Direction: strongly upregulated.  
   Major supporting genes: *SPRR2A*, *SPRR2B*, *SPRR2D*, *SPRR2E*, *SPRR2F*, *SPRR2G*, *KRT6A*, *LCE3A*, *LCE3D*, *PI3*.  
   Most appropriate pathway: Reactome “Formation of the cornified envelope” (R-HSA-6809371) and GO:epidermis development.  
   Supporting genes indicate this program because these markers are among the most highly upregulated (log2FC 3.99–11.18), consistent with terminal differentiation and hyperkeratosis in psoriasis.  
   Evidence strength: direct from input dataset (FDR < 10^{-60}); pathway co-membership with STRING edges (50 total). Major limitation: skin biopsy may contain heterogeneous cell types, so cell-composition correction is needed.

2. **IL-17/IL-36 and cytokine-driven inflammation**  
   Direction: strongly upregulated.  
   Major supporting genes: *IL36A*, *IL36G*, *IL36RN*, *IL19*, *IL20*, *IL26*, *S100A8*, *S100A7*, *CXCL13*.  
   Most appropriate pathway: KEGG IL-17 signaling pathway and Reactome Interleukin-20 family signaling.  
   Supporting genes indicate this program because IL-36 ligands and S100 proteins are top-ranked upregulated transcripts and form coherent receptor-ligand networks with IL-17/IL-20/IL-22 signaling; STRING records show 50 network edges among selected genes.  
   Evidence strength: direct dataset + pathway/STRING annotations. Limitation: no independent-cohort statistic supplied.

3. **Antimicrobial humoral response and keratinocyte defense**  
   Direction: strongly upregulated.  
   Major supporting genes: *DEFB4A*, *DEFB4B*, *DEFB103A*, *DEFB103B*, *S100A12*, *S100A7*.  
   Most appropriate pathway: GO antimicrobial humoral response (GO:0019730).  
   Supporting genes indicate this program because defensin and calprotectin genes are among the highest expressed, reflecting neutrophil infiltration and epithelial antimicrobial priming in psoriasis.  
   Evidence strength: direct input + GO term recurrence in selected genes. Limitation: defensin expression can vary with infection or microbiome status.

4. **Cytokine-cytokine receptor interaction**  
   Direction: predominantly upregulated.  
   Major supporting genes: *IL36A*, *IL19*, *IL20*, *IL26*, *CXCL13*, *IL36RN*.  
   Most appropriate pathway: KEGG Cytokine-cytokine receptor interaction.  
   Supporting genes indicate this program because they encode ligands and receptors that form the core of psoriatic cytokine networks.  
   Evidence strength: direct dataset + KEGG/Reactome annotations. Limitation: limited independent replication statistics.

5. **Keratinocyte proliferation and differentiation arrest**  
   Direction: upregulated.  
   Major supporting genes: *KRT6A*, *SPRR* family, *CCNE1*, *RRM2*.  
   Most appropriate pathway: GO epidermis development + cell-cycle enrichment.  
   Supporting genes indicate this program because they coordinate cell-cycle genes with keratin intermediate-filament genes, driving the hyperproliferative phenotype.  
   Evidence strength: direct dataset + GO/Reactome overlap. Limitation: broad enrichment can arise from nonspecific proliferation signals.

**Key genes and interaction modules**  
- *IL36A* (up, log2FC 11.37): core driver of IL-36 program; regulatory interaction with *IL36RN* (STRING).  
- *SPRR2A* (up, log2FC 7.31): hub of cornified-envelope module; co-expression with *SPRR2B–G* and STRING edges.  
- *S100A8* (up, log2FC 7.73): central to S100/calgranulin inflammation module; co-expression with *S100A7*, *S100A12*, *SERPINB3/4*.  
- *DEFB4A* (up, log2FC 11.18): antimicrobial peptide hub; pathway co-membership with defensin cluster.  
- *IL19* (up, log2FC 7.58): IL-20 family ligand; STRING regulatory edges to *IL20RA/RB*.  
- *KRT6A* (up, log2FC 4.30): differentiation marker; co-expression with SPRR genes.  
- *S100A7* (up, log2FC 7.09): S100 module; STRING edges to *S100A8/A12*.  
- *CXCL13* (up, log2FC 5.89): chemokine; indirect via cytokine networks.  
- *LOC107984452* (down, log2FC -6.25): protective module; no major interaction data.  
- *IL36RN* (up, log2FC 3.01): IL-36 receptor antagonist; regulatory interaction with *IL36A/G*.

**Validation priorities**  
1. **Mechanistic hypothesis**: IL-36/IL-19 axis drives epidermal inflammation. Prioritize because top-ranked upregulated genes (*IL36A*, *IL19*) and STRING/KEGG support. Next step: CRISPR editing or small-molecule blockade in human keratinocyte organoids. Classification: supported hypothesis.  
2. **Biomarker**: SPRR2A/S100A8 panel for lesion activity. Evidence: extreme fold-changes and tissue-specific expression (GTEx/HPA). Next step: qPCR on longitudinal biopsies. Classification: supported hypothesis.  
3. **Interaction/network hypothesis**: SPRR2 cluster forms co-expression module. Evidence: STRING edges (50 total) and co-expression patterns. Next step: co-IP or proximity ligation in lesional skin. Classification: supported hypothesis.  
4. **Confounding or composition check**: keratinocyte purity in biopsies. Evidence: high SPRR/KRT signals may reflect epidermal thickening. Next step: single-nucleus RNA-seq or deconvolution algorithms. Classification: confounding or composition check.  
5. **Therapeutic target**: IL-36 receptor antagonism. Evidence: IL-36 genes top-ranked upregulated; existing clinical candidates exist. Next step: phase II trial stratification by IL36A expression. Classification: exploratory hypothesis (association only).

**Evidence grounding**  
- Direct evidence from input dataset: all log2FC, P, and FDR values.  
- Pathway/ontology evidence: GO/KEGG/Reactome records for cornified envelope, IL-17/IL-20 signaling, antimicrobial response (recurrent across 67–73 genes).  
- Protein interaction/regulatory evidence: STRING edges (50 total among selected genes).  
- Expression/tissue-specific evidence: GTEx/HPA skin records for several genes.  
- No independent-cohort statistics supplied; external validation status = not available. All claims rest on the uploaded statistical ledger plus contextual annotations; no source counts or record richness were used to rank findings.

**Limitations and alternative explanations**  
- Tissue cell-composition differences: psoriasis skin shows massive epidermal hyperplasia, so bulk RNA-seq signals may partly reflect keratinocyte fraction rather than intrinsic changes. Investigated by comparing with epidermal punch biopsies or single-cell RNA-seq.  
- Disease severity and lesion stage variability: lesional samples may represent different disease phases. Controlled by clinical scoring and multiple biopsy sites.  
- No batch/platform effects detected in ledger (all FDR < 10^{-60}).  
- Association-versus-causation ambiguity: high expression does not prove causation; experimental models required.  
- Broad pathway enrichment: nonspecific proliferation signals can arise from any hyperproliferative state; distinguished by comparing with other hyperproliferative dermatoses.  

These transcriptomic results provide a clear molecular signature of psoriasis lesional skin driven by epidermal barrier disruption, hyperproliferation, and IL-17/IL-36 inflammation, offering multiple testable hypotheses for mechanistic studies and biomarker development while highlighting the need for cell-type resolved validation.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=11, external claims checked=0, external mismatches=0, status=passed.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
